Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 1

Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC

,

Panelists discuss how, when discussing frontline regimens for EGFR-mutated non–small cell lung cancer (NSCLC), the NCCN-recommended options include osimertinib monotherapy for its targeted approach with lower toxicity; amivantamab/lazertinib combination for potentially deeper responses in specific mutations; and osimertinib with platinum-doublet chemotherapy for more aggressive disease requiring enhanced tumor control.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC
    EP. 2: EGFR-Mutated NSCLC Disease Risk Stratification
    EP. 3: Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC
    EP. 4: Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
    EP. 5: Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC
    EP. 6: Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC
    EP. 7: Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC
    EP. 8: Future Treatment Options in EGFR-Mutant NSCLC

    Video content above is prompted by the following:

    • When discussing initial treatment options, how do you present the 3 recommended NCCN frontline regimens to patients: osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with a platinum-containing doublet?
    x